Siatis Perry C 4

What Happened Perry C. Siatis, Executive Vice President, General Counsel and Secretary of AbbVie Inc., was granted/received performance-based equity on February 18, 2026. The filing reports 33,518 shares of AbbVie common stock issued under performance awards (granted in prior years) and a derivative award option covering 19,500 shares. All reported acquisitions show a $0 price (awards/options); the total count across awards and the option is 53,018 underlying shares, with the performance shares to be issued on February 28, 2026.

Key Details

• Transaction date: February 18, 2026; Form 4 filed February 20, 2026 (appears timely).
• Reported items:
  • 16,290 shares (performance share award; footnote F1)
  • 5,792 shares (performance-vesting RSU; F2)
  • 5,628 shares (performance-vesting RSU; F3)
  • 5,808 shares (performance-vesting RSU; F4)
  • 19,500-share employee stock option (derivative; F5)
• Price: $0.00 for all reported acquisitions (awards/options).
• Shares owned after the transactions: not disclosed in the provided filing.
• Notable footnotes:
  • F1–F4: These are performance-based awards granted in 2023–2025 whose vesting restrictions were certified as met; shares will be issued on Feb 28, 2026.
  • F5: Employee stock option granted under AbbVie’s 2013 Incentive Stock Program; becomes exercisable in annual increments of 6,500 on Feb 18 of 2027, 2028 and 2029. Transaction exempt from Section 16 under Rule 16b-3.

Context These entries are awards and an option grant/release of performance restrictions, not open-market purchases or sales. Performance awards are typically part of executive compensation and reflect previously granted awards having met performance criteria; they do not necessarily signal the insider buying or selling stock. The option is a standard grant with staged exercisability over 2027–2029.